Korean Drug Co. Ltd Asset Resilience Ratio
Korean Drug Co. Ltd asset resilience ratio. Korean Drug Co. Ltd (014570) has an Asset Resilience Ratio of 25.41% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 014570 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Korean Drug Co. Ltd (2014–2025)
Asset resilience ratio of Korean Drug Co. Ltd from 2014 to 2025. This chart shows how Korean Drug Co. Ltd's Asset Resilience Ratio has changed over time. Read 014570 liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Korean Drug Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Korean Drug Co. Ltd (014570) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩25.13 Billion | 25.41% |
| Total Liquid Assets | ₩25.13 Billion | 25.41% |
Asset Resilience Insights
- Very High Liquidity: Korean Drug Co. Ltd maintains exceptional liquid asset reserves at 25.41% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Korean Drug Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Korean Drug Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
AstraZeneca PLC
LSE:AZN |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Int'L Group Co Ltd
SHE:000411 |
Drug Manufacturers - General | 0.00% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Korean Drug Co. Ltd Asset Resilience Ratio by Year (2014–2025)
Korean Drug Co. Ltd asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Korean Drug Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 26.62% | ₩25.11 Billion ≈ $17.02 Million |
₩94.32 Billion ≈ $63.92 Million |
+5.29pp |
| 2024-12-31 | 21.33% | ₩18.96 Billion ≈ $12.85 Million |
₩88.89 Billion ≈ $60.24 Million |
+2.78pp |
| 2023-12-31 | 18.55% | ₩16.64 Billion ≈ $11.28 Million |
₩89.71 Billion ≈ $60.79 Million |
-9.21pp |
| 2022-12-31 | 27.76% | ₩26.23 Billion ≈ $17.78 Million |
₩94.52 Billion ≈ $64.05 Million |
-3.52pp |
| 2021-12-31 | 31.28% | ₩27.72 Billion ≈ $18.78 Million |
₩88.61 Billion ≈ $60.05 Million |
+4.80pp |
| 2020-12-31 | 26.48% | ₩22.07 Billion ≈ $14.95 Million |
₩83.34 Billion ≈ $56.48 Million |
+11.50pp |
| 2019-12-31 | 14.98% | ₩11.36 Billion ≈ $7.70 Million |
₩75.85 Billion ≈ $51.40 Million |
+3.16pp |
| 2018-12-31 | 11.82% | ₩8.62 Billion ≈ $5.84 Million |
₩72.96 Billion ≈ $49.45 Million |
+7.10pp |
| 2017-12-31 | 4.71% | ₩3.15 Billion ≈ $2.13 Million |
₩66.79 Billion ≈ $45.27 Million |
-1.58pp |
| 2016-12-31 | 6.30% | ₩3.99 Billion ≈ $2.71 Million |
₩63.41 Billion ≈ $42.97 Million |
+5.71pp |
| 2015-12-31 | 0.59% | ₩350.05 Million ≈ $237.22K |
₩59.20 Billion ≈ $40.12 Million |
+0.58pp |
| 2014-12-31 | 0.01% | ₩4.68 Million ≈ $3.17K |
₩62.17 Billion ≈ $42.13 Million |
-- |
About Korean Drug Co. Ltd
Korean Drug Co., Ltd. manufactures and sells medicines for treating various diseases in South Korea. The company offers Medicines for urinary tract disease, digestive system, circulatory system, psychonervous system, central nervous system, respiratory system, and skin and subcutaneous system; and antivirals, antibiotics, antifungals, antipyretic, analgesis, anti-inflammatory, and other products.… Read more